



# Louisiana

## Pharmacogenetic Testing for Pain Management

**Policy #** 00468

**Original Effective Date:** 04/20/2015

**Current Effective Date:** 08/10/2020

*Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.*

*Note: Genetic Testing for Diagnosis and Management of Mental Health Conditions is addressed separately in medical policy 00402.*

*Note: Cytochrome P450 Genotype-Guided Treatment Strategy is addressed separately in medical policy 00169.*

### Services Are Considered Investigational

*Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.*

Based on review of available data, the Company considers genetic testing for pain management for all indications to be **investigational**.\*

### Policy Guidelines

This policy does not address testing limited to cytochrome p450 genotyping. This policy also does not address testing for congenital insensitivity to pain.

Commercially available genetic tests for pain management consist of panels of single-nucleotide variants (SNVs) or (less commonly) individual SNV testing. SNVs implicated in pain management include the following (see also Table 1):

- *5HT2C* (serotonin receptor gene)
- *5HT2A* (serotonin receptor gene)
- *SLC6A4* (serotonin transporter gene)
- *DRD1* (dopamine receptor gene)
- *DRD2* (dopamine receptor gene)
- *DRD4* (dopamine receptor gene)
- *DAT1* or *SLC6A3* (dopamine transporter gene)
- *DBH* (dopamine beta-hydroxylase gene)

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

- *COMT* (catechol *O*-methyltransferase gene)
- *MTHFR* (methylenetetrahydrofolate reductase gene)
- $\gamma$ -aminobutyric acid (GABA) A receptor gene
- *OPRM1* ( $\mu$ -opioid receptor gene)
- *OPRK1* ( $\kappa$ -opioid receptor gene)
- *UGT2B15* (uridine diphosphate glycosyltransferase 2 family, member 15)
- Cytochrome p450 genes: *CYP2D6*, *CYP2C19*, *CYP2C9*, *CYP3A4*, *CYP2B6*, *CYP1A2*.

### Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society’s nomenclature is recommended by the Human Variome Project, the HUman Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology-“pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”-to describe variants identified that cause Mendelian disorders.

**Table PG1. Nomenclature to Report on Variants Found in DNA**

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

**Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification**

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

### Genetic Counseling

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Please see Codes table for details.

## Background/Overview

### Pain

The Institute of Medicine reported in 2011 that common chronic pain conditions affect at least 116 million adults in the U. S. Chronic pain may be related to cancer, or be what is termed *chronic noncancer pain*, which may be secondary to a wide range of conditions, such as migraines, low back pain, or fibromyalgia. Multiple therapeutic options exist to manage pain, including pharmacotherapies, behavioral modifications, and physical and occupational therapy, and

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

complementary/alternative therapies. Nonetheless, the Institute of Medicine has reported that many individuals receive inadequate pain prevention, assessment, and treatment. Given that pain is an individual and subjective experience, assessing and predicting response to pain interventions, including pain medications, is challenging.

### **Management**

A variety of medication classes are available to manage pain: nonopioid analgesics, including acetaminophen and nonsteroidal anti-inflammatory drugs, opioid analgesics, which target central nervous system pain perception, and classes of adjuvants, including antiepileptic drugs (eg, gabapentin, pregabalin), antidepressants (eg, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors), and topical analgesics. The management of chronic pain has been driven, in part, by the World Health Organization's analgesic ladder for pain management, which was developed to manage cancer-related pain but has been applied to other forms of pain. The ladder outlines a stepped approach to pain management, beginning with nonopioid analgesia and proceeding to a weak opioid (eg, codeine), with or without an adjuvant for persisting pain, and subsequently to a strong opioid (eg, fentanyl, morphine), with or without an adjuvant for persisting or worsening pain. Various opioids are available in short- and long-acting preparations and administered through different routes, including oral, intramuscular, subcutaneous, sublingual, and transdermal.

### **Pharmacologic Treatment**

For acute pain management, particularly postoperative pain, systemic opioids and nonopioid analgesics remain a mainstay of therapy. However, there has been growing interest in using an alternative, nonsystemic treatments in addition to or as an alternative to systemic opioids. These options include neuraxial anesthesia, including intraoperative epidural or intrathecal opioid injection, which can provide pain relief for up to 24 hours postoperatively, and postoperative indwelling epidural anesthesia with opioids and local anesthetics, which may be controlled with a patient-controlled anesthesia pump. Postoperative peripheral nerve blocks may also be used.

While available pain management therapies are effective for many patients, there is a high degree of heterogeneity in pain response, particularly for chronic pain. In addition, many opioids are associated with a significant risk of adverse events, ranging from mild (eg, constipation) to severe (eg, respiratory depression), and are associated with risk of dependence, addiction, and abuse. Limitations in currently available pain management techniques have led to an interest in the use of

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

pharmacogenetics to improve the targeting of therapies and prediction and avoidance of adverse events.

### Genetics of Pain Management

Genetic factors may contribute to a range of aspects of pain and pain control, including predisposition to conditions that lead to pain, pain perception, and the development of comorbid conditions that may affect pain perception. Currently available genetic tests relevant to pain management assess single-nucleotide variants in single genes potentially relevant to pharmacokinetic or pharmacodynamic processes.

Genes related to these clinical scenarios include, broadly speaking, those involved in neurotransmitter uptake, clearance, and reception; opioid reception; and hepatic drug metabolism. Panels of genetic tests have been developed and proposed for use in the management of pain. Genes identified as being relevant to pain management are summarized in Table 1.

**Table 1. Genes Relevant to Pain Management**

Gene	Locus	Gene Product Function
<i>5HT2C</i> (serotonin receptor gene)	Xq23	1 of 6 subtypes of serotonin receptor, which is involved in release of dopamine and norepinephrine
<i>5HT2A</i> (serotonin receptor gene)	13q14-21	Another serotonin receptor subtype
<i>SLC6A4</i> (serotonin transporter gene)	17q11.2	Clears serotonin metabolites from synaptic spaces in the CNS
<i>DRD1</i> (dopamine receptor gene)	5q35.2	G-protein-coupled receptors that have dopamine as their ligands
<i>DRD2</i> (dopamine receptor gene)	11q23.2	
<i>DRD4</i> (dopamine receptor gene)	11p15.5	
<i>DAT1</i> or <i>SLC6A3</i> (dopamine transporter gene)	5p15.33	Mediates dopamine reuptake from synaptic spaces in the CNS

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

Gene	Locus	Gene Product Function
<i>DBH</i> (dopamine beta-hydroxylase gene)	9q34.2	Catalyzes the hydroxylase of dopamine to norepinephrine; active primarily in adrenal medulla and postganglionic synaptic neurons
<i>COMT</i> (catechol <i>O</i> -methyl-transferase gene)	22q11.21	Responsible for enzymatic metabolism of catecholamine neurotransmitters dopamine, epinephrine, and norepinephrine
<i>MTHFR</i> (methylenetetrahydrofolate reductase gene)	1p36.22	Converts folic acid to methylfolate, a precursor to norepinephrine, dopamine, and serotonin neurotransmitters
GABA A receptor gene	5q34	Ligand-gated chloride channel that responds to GABA, a major inhibitory neurotransmitter
<i>OPRM1</i> ( $\mu$ -opioid receptors gene)	6q25.2	G-protein coupled receptor that is primary site of action for commonly used opioids, including morphine, heroin, fentanyl, and methadone
<i>OPRK1</i> ( $\kappa$ -opioid receptor gene)	8q11.23	Binds the natural ligand dynorphin and synthetic ligands
<i>UGT2B15</i> (uridine diphosphate glycosyltransferase 2 family, member 15)	4q13.2	Member of UDP family involved in the glycosylation and elimination of potentially toxic compounds
Cytochrome p450 genes		
<i>CYP2D6</i>	22q13.2	

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

Gene	Locus	Gene Product Function
<i>CYP2C19</i>	10q23.33	Hepatic enzymes responsible for the metabolism of a wide variety of medications, including analgesics
<i>CYP2C9</i>	10q23.33	
<i>CYP3A4</i>	7q22.1	
<i>CYP2B6</i>	19q13.2	
<i>CYP1A2</i>	15q24.1	

CNS: central nervous system; GABA: g-aminobutyric acid; UDP: uridine diphosphate glycosyltransferase.

### Commercially Available Genetic Tests for Pain Management

Several test labs market panel tests or individual tests designed to address one or more aspects of pain management, including but not limited to drug selection, drug dosing, or prediction of adverse events. Specific variants included in the panels are shown in Table 2.

GeneSight Analgesic (Assurex Health) is a genetic panel test intended to analyze “how patients’ genes can affect their metabolism and possible response to FDA [U.S. Food and Drug Administration]-approved opioids, NSAIDs and muscle relaxants commonly used to treat chronic pain.” Results are provided with a color-coded report based on efficacy and tolerability, which displays those medications that should be used as directed, used with caution, or used with increased caution and more frequent monitoring. The company’s website does not specify testing methods. Publications describing other tests provided by the company specify that testing is conducted via single-nucleotide variants sequencing performed via a multiplex polymerase chain reaction.

Pain Medication DNA Insight (Pathway Genomics) is a panel test intended to identify genetic variants that affect how an individual will respond to the analgesic effects of certain types of pain medications. The results report includes the genotype/single-nucleotide variants for each gene included, along with a description of the toxicity risk, the dose required, medication efficacy, or plasma concentration based on genotype results for a range of medications used for pain management, primarily opioids. The testing method is not specified on the company’s website.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

Millennium PGT<sup>SM</sup>‡ (Pain Management) (Millennium Health) is a genetic panel test intended to help physicians select pain medication. The panel analyzes 11 genes related to pain management; results are provided with a proprietary Millennium Analysis of Patient Phenotype report that provides decision support for medications that may be affected by the patient’s genotype.

Molecular Testing Labs<sup>TM</sup>‡ Pain Management Panel (Molecular Testing Labs) is a panel designed to evaluate the metabolism of pain relievers. The manufacturer’s website states the test evaluates “a number of relevant genes coding for the metabolism of a wide variety of pain relief drugs,” but the specific genes analyzed are not readily described.

Genelex offers several pharmacogenomic panels, one of which (the YouScript<sup>®</sup>‡ Analgesic Panel) focuses on genes relevant to pain management.

AltheaDx offers IDgenetix pain tests that analyze the genes and genetic variants involved in the metabolism of opioids, nonsteroidal anti-inflammatory drugs, and other pain drugs as well as variations in pharmacodynamic genes, such as the μ-opioid receptor gene (*OPRM1*).

Other laboratories, including CompanionDx, ARUP Laboratories, and AIBioTech, which markets the PersonaGene Genetic Panel, offer panels of *CYP450* genes.

In addition to the available panel tests, several labs offer genetic testing for individual genes that are included in some of the panels, including the *MTFHR*, *CYP450*, and *OPRM1* genes (see Table 2).

**Table 2. Genes Included in Commercially Available Genetic Panels for Pain Management**

Gene	Potential Role in Pain Management
<i>COMT</i>	Val158Met variant associated with alterations in emotional processing and executive function. Other variants have been associated with pain sensitivity
<i>MTHFR</i>	Multiple variants identified, which are associated with a wide variety of clinical disorders
<i>GABA</i>	1519T>C GABA A 6 gene variant associated with methamphetamine dependence

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

<i>OPRK1</i> ( $\kappa$ -opioid receptor)	Variants associated with the risk for opioid addiction
<i>OPRM1</i> ( $\mu$ -opioid receptor)	<i>A118G</i> variant (rs1799971) associated with reduced pain sensitivity and opioid requirements
<i>VKORC1</i>	
<i>UGT2B15</i>	Tamoxifen, diclofenac, naloxone, carbamazepine, and benzodiazepines inhibit UGT2B7 potentially leading to opioid hyperalgesia
<i>CYP</i> genes	Hepatic enzymes responsible for the metabolism of a wide variety of medications, including analgesics
• <i>CYP2D6</i>	<i>CYP2D6</i> is primary metabolizer for multiple oral opioids; metabolizer phenotype associated with variability in opioid effects
• <i>CYP2C19</i>	•
• <i>CYP3A4</i>	Involved in metabolism of up to 60% of clinically used drugs
• <i>CYP1A2</i>	•
• <i>CYP2C9</i>	•
• <i>CYP2B6</i>	
• <i>CYP3A5</i>	

CYP: cytochrome; GABA: g-aminobutyric acid.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

## **FDA or Other Governmental Regulatory Approval**

### **U.S. Food and Drug Administration (FDA)**

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. The GeneSight Analgesic panel, the Pathway Genomics Pain Medication DNA Insight panel, the Millennium PGT (Pain Management) panel, and YouScript Analgesic panel are available under the auspices of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. FDA has chosen not to require any regulatory review of this test.

No genetic tests approved by the FDA for pain management were identified.

## **Rationale/Source**

While multiple pharmacologic therapies are available for the management of acute and chronic pain, there is a high degree of heterogeneity in pain response, particularly in the management of chronic pain, and in adverse events. Testing for genetic variants that are relevant to pharmacokinetics or pharmacodynamics of analgesics may assist in selecting and dosing drugs affected by these genetic variants.

For individuals who have a need for pharmacologic pain management who receive pharmacogenetic testing to target therapy, the evidence includes a prospective cohort study with historical controls that assessed genotype-guided management of postoperative pain and a pragmatic cluster trial that evaluated chronic pain control when treatment was guided by a combination of pharmacogenetic and drug inhibition of CYP2D6. The relevant outcomes are symptoms, health status measures, medication use, and treatment-related morbidity. The prospective cohort study reported on the use of genetic panel test results to guide the selection of analgesics in a postoperative setting and reported statistically significant improvement in total scores of a composite endpoint that measured analgesia, patient satisfaction, and the impact of drug-associated side effects vs historical controls. However, methodologic limitations precluded assessment of the effects on outcomes. The prospective cluster trial evaluated a combination of pharmacogenetic and drug inhibition of CYP2D6, finding a statistically significant but modest improvement in chronic pain control in the intermediate and poor

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Pharmacogenetic Testing for Pain Management

Policy # 00468  
 Original Effective Date: 04/20/2015  
 Current Effective Date: 08/10/2020

metabolizers. The effect of pharmacogenetic testing alone cannot be determined from this trial. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Supplemental Information**  
**Practice Guidelines and Position Statements**

**American Academy of Neurology**

The American Academy of Neurology (2014) published a position paper on the use of opioids for chronic noncancer pain. Regarding pharmacogenetic testing, the guidelines stated that genotyping to determine whether the response to opioid therapy can or should be more individualized is an emerging issue that will “require critical original research to determine effectiveness and appropriateness of use.”

**U.S. Preventive Services Task Force Recommendations**

Not applicable.

**Medicare National Coverage**

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

**Ongoing and Unpublished Clinical Trials**

Some currently ongoing and unpublished trials that might influence this review are listed in Table 3.

**Table 3. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT03534063	Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery	260	Mar 2020

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

NCT03498014	Comparison of Standard Opioid Prescription Versus Prescription Guided by Pharmacogenetic Analysis in Patients With Non-cancerous Chronic Pain.	80	Apr 2020
NCT03772535	Using Pharmacogenetics to Structure Individual Pain Management Protocols for Joint Replacement Patients	50	Dec 2020
NCT01140724	Predicting Perioperative Opioid Adverse Effects and Personalizing Analgesia in Children	1200	Apr 2021
<i>Unpublished</i>			
NCT02081872 <sup>a</sup>	Utility of PharmacoGenomics for Reducing Adverse Drug Effects	297,000	Jul 2017 (unknown)

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

## **References**

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, “Pharmacogenetic Testing for Pain Management”, 2.04.131, 12:2019.
2. Institute of Medicine, Committee on Advancing Pain Research Care and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington (DC): National Academies Press; 2011.
3. GeneSight. GeneSight Analgesic. <http://genesight.com/clinicians/genesight-tests/analgesic/>.
4. Carma Nabavi PG. Personal Communication. 2014.
5. Labs MT. Pain Management Panel. <http://moleculartestinglabs.com/pain-drug-interaction-panel-clinician>.
6. Genelex. Clinically Actionable Pharmacogenetic Tests. n.d.; <http://genelex.com/pharmacogenetic-tests/>.
7. Senagore AJ, Champagne BJ, Dosokey E, et al. Pharmacogenetics-guided analgesics in major abdominal surgery: Further benefits within an enhanced recovery protocol. *Am J Surg*. Mar 2017;213(3):467-472. PMID 27955884.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

8. Smith DM, Weitzel KW, Elsey AR et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. *Genet. Med.*, 2019 Jan 24;21(8). PMID 30670877.
9. Franklin GM. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. *Neurology*. Sep 30 2014;83(14):1277-1284. PMID 25267983

### Policy History

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

- 04/02/2015 Medical Policy Committee review
  - 04/20/2015 Medical Policy Implementation Committee approval. New policy.
  - 04/07/2016 Medical Policy Committee review
  - 04/20/2016 Medical Policy Implementation Committee approval. No change to coverage.
  - 01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
  - 07/06/2017 Medical Policy Committee review
  - 07/19/2017 Medical Policy Implementation Committee approval. No change to coverage.
  - 07/05/2018 Medical Policy Committee review
  - 07/11/2018 Medical Policy Implementation Committee approval. No change to coverage. Added policy guidelines.
  - 07/03/2019 Medical Policy Committee review
  - 07/18/2019 Medical Policy Implementation Committee approval. No change to coverage.
  - 07/02/2020 Medical Policy Committee review
  - 07/08/2020 Medical Policy Implementation Committee approval. No change to coverage.
- Next Scheduled Review Date: 07/2021

### Coding

*The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2019 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.*

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

*The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.*

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	0029U, 0031U, 0032U, 0078U, 81225, 81226, 81227, 81291, 81401, 81479
HCPCS	No codes
ICD-10 Diagnosis	All related diagnoses

\*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety,

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





## Pharmacogenetic Testing for Pain Management

Policy # 00468

Original Effective Date: 04/20/2015

Current Effective Date: 08/10/2020

effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

**NOTICE:** If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.